
Sign up to save your podcasts
Or


Thomas Phillips argues that the lengthy FDA drug approval process is a significant barrier to both public health and economic growth. While the government successfully evaluates product safety quickly, the authors contend that the secondary mandate to prove long-term effectiveness creates a "one-size-fits-all" bureaucratic delay that can last a decade. By shortening this timeline and allowing the private sector and individual patients to determine a treatment's utility, the study suggests the United States could unlock up to $48 trillion in economic benefits.
Learn more about your ad choices. Visit megaphone.fm/adchoices
By 77 WABC4.6
3434 ratings
Thomas Phillips argues that the lengthy FDA drug approval process is a significant barrier to both public health and economic growth. While the government successfully evaluates product safety quickly, the authors contend that the secondary mandate to prove long-term effectiveness creates a "one-size-fits-all" bureaucratic delay that can last a decade. By shortening this timeline and allowing the private sector and individual patients to determine a treatment's utility, the study suggests the United States could unlock up to $48 trillion in economic benefits.
Learn more about your ad choices. Visit megaphone.fm/adchoices

23,356 Listeners

2,306 Listeners

12,924 Listeners

741 Listeners

5,659 Listeners

6,583 Listeners

43,953 Listeners

734 Listeners

6,298 Listeners

487 Listeners

600 Listeners

925 Listeners

216 Listeners

387 Listeners

1,174 Listeners